Mikart Doubles Down in Atlanta with New HQ, Major Plant Expansion

ATLANTA, GA – April 28, 2026 – Pharmaceutical contract manufacturer Mikart today celebrated a significant strategic advancement with the official ribbon cutting of its new executive headquarters in Northwest Atlanta. The move, part of a dual investment strategy, runs parallel to a major manufacturing expansion set to increase its bottling capacity by over 50%, positioning the company to meet surging global demand and reinforcing its half-century commitment to the Atlanta region.

A Strategic Move for Growth and Collaboration

The new 13,000-square-foot headquarters, located at Cumberland Center II, represents a pivotal step in the company's long-term growth plan, first announced in September 2025. By relocating its executive and administrative functions, Mikart establishes a modern, centralized hub designed to enhance collaboration and support its expanding team. More critically, the move frees up valuable space at its nearby manufacturing campus, which will be repurposed for expanded serialized packaging operations.

"This ribbon cutting marks an exciting new chapter for Mikart," said Michael Kallelis, Chief Executive Officer, during the ceremony. "Our new headquarters provides the space and infrastructure needed to support our growing team and evolving business while reinforcing our commitment to operational excellence and innovation."

This commitment is rooted in a long history. Founded in 1975 and having recently celebrated its 50th anniversary, Mikart has become a fixture in Atlanta’s life sciences landscape. The decision to keep both its new headquarters and its manufacturing operations within the city underscores a deep-seated dedication to the local economy and its role as a key regional employer.

Addressing the Industry's Capacity Crunch

Beyond the new corporate offices, the concurrent expansion of Mikart's manufacturing capabilities addresses a critical need within the global pharmaceutical industry. The company is significantly boosting its oral solid dosage (OSD) bottling and downstream packaging operations. This initiative, scheduled for completion and operational start-up in the fourth quarter of 2026, will increase bottling capacity by more than 50%.

This expansion is a direct response to a rapidly growing market. The global OSD contract development and manufacturing organization (CDMO) sector was valued at approximately $46.37 billion in 2025 and is projected to surge to over $77 billion by 2033. This growth is driven by pharmaceutical and biotech firms increasingly outsourcing manufacturing to streamline their operations, reduce costs, and focus on their core competencies of drug discovery and commercialization. OSD forms like tablets and capsules constitute over half of all pharmaceutical products consumed globally, creating sustained and intense demand for reliable manufacturing partners.

Mikart's investment aims to capture this opportunity and enhance supply chain resilience for its partners. By increasing capacity, the company can improve production efficiency, shorten lead times, and scale its operations alongside its clients' needs.

"The combination of our new headquarters and expanded manufacturing capabilities positions Mikart for continued, sustainable growth," noted Scott Neola, Chief Financial Officer. "We are making disciplined investments to strengthen our infrastructure, improve efficiency, and ensure we can scale alongside our partners."

A Legacy of Innovation and Technical Advancement

This latest expansion is not an isolated event but the continuation of a multi-year strategy focused on technological investment and capability enhancement. Mikart has consistently upgraded its facilities to offer comprehensive, end-to-end solutions from development to commercial-scale production.

In March 2024, the company announced the integration of advanced Fette® double-sided tablet presses, high-speed machines equipped with automatic weight control and metal detection systems that significantly enhance production volume and flexibility. This followed the completion of a new, state-of-the-art liquids and suspensions suite in February 2023, designed to manufacture complex liquid dosage forms for pediatric and geriatric populations, with temperature-controlled tanks supporting volumes from 50 to 4,000 liters.

Packaging capabilities have also been a key focus. The company's six packaging lines already feature full serialization—a critical track-and-trace technology for ensuring drug safety and regulatory compliance—and can fill over 250,000 bottles per day. In September 2023, Mikart acquired a Flexpack NF-150 sachet-packaging machine to meet rising demand for alternative dosage formats. These capabilities are further enhanced by the company's expertise in handling DEA-controlled substances, a specialized area requiring stringent adherence to FDA and GMP guidelines.

Further demonstrating its commitment to innovation, Mikart has also pursued strategic partnerships, including a collaboration with Nano PharmaSolutions to expand its NanoTransformer® manufacturing capabilities. This technology addresses one of the industry's most persistent challenges: improving the solubility and bioavailability of poorly absorbed drug compounds, potentially making new therapies more effective.

Bolstering Atlanta's Burgeoning Biotech Ecosystem

By choosing to expand within Atlanta, Mikart is providing a significant boost to the city's reputation as a growing hub for biotechnology and life sciences. The company’s long-standing presence and continued investment contribute directly to the region's economic vitality through high-skill employment and local spending.

While Mikart currently employs around 160 individuals, this dual expansion signals a trajectory of growth that promises to further support the local workforce. The repurposing of existing campus space for sophisticated, serialized packaging operations, in particular, reinforces the company's role in cultivating a high-tech manufacturing ecosystem in the area.

This strategic reinvestment in its Atlanta footprint sends a strong signal to the broader industry that the region possesses the infrastructure, talent, and business environment necessary to support world-class pharmaceutical manufacturing. As Mikart embarks on its next chapter, its growth is intrinsically linked with that of its home city, creating a powerful synergy that strengthens both the company and the community it has been a part of for over five decades.